Literature DB >> 25916314

Is Clinic Visit Frequency Associated with Weight Gain During the Interstage Period? A Report from the Joint Council on Congenital Heart Disease National Pediatric Cardiology Quality Improvement Collaborative (JCCHD-NPCQIC).

David M Hurst1,2, Matthew E Oster1,2,3, Sherry Smith1, Martha L Clabby4,5,6.   

Abstract

Growth problems are prevalent among infants with congenital heart disease. We sought to determine whether frequency of outpatient clinic visits correlated with weight gain in patients with hypoplastic left heart syndrome or variant during the interstage period between discharge from stage I palliation and presentation for stage II palliation (SIIP). Using prospectively collected data from the JCCHD NPC-QIC database from June 2008 to July 2013, we performed a retrospective cohort study assessing the association of days between clinic visits (DBV) with the change in weight-for-age z-score (WAZ) during the interstage period. Eligible subjects were those who survived to a SIIP performed at <270 days of age and had at least two outpatient clinic visits. There were 561 patients from 49 centers who fulfilled inclusion criteria. The average interstage change in WAZ was +0.22. The mean number of DBV was 16.1 days, and the average number of clinic visits was six. There was no correlation of change in WAZ with either DBV (r = 0.02, P = 0.62) or the number of visits (r = 0.03, P = 0.44). Subjects within this cohort are seen about every 2 weeks averaged over the interstage period. There is no correlation between interstage visit frequency and change in WAZ in this patient population. Further research is needed to describe differences in visit frequency as the patient progresses through the interstage period and to elucidate whether patient factors such as growth velocity are influencing visit frequency. The optimal visit frequency remains unknown.

Entities:  

Keywords:  Cardiology outpatient visit frequency; Hypoplastic left heart syndrome; Interstage period; Stage I palliation; Stage II palliation; Weight-for-age z-score

Mesh:

Year:  2015        PMID: 25916314     DOI: 10.1007/s00246-015-1169-6

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  14 in total

1.  The impact of a dedicated single-ventricle home-monitoring program on interstage somatic growth, interstage attrition, and 1-year survival.

Authors:  Christopher J Petit; Charles D Fraser; Raphael Mattamal; Timothy C Slesnick; Constance E Cephus; Elena C Ocampo
Journal:  J Thorac Cardiovasc Surg       Date:  2011-06-24       Impact factor: 5.209

2.  Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network.

Authors:  J D Horbar; J Rogowski; P E Plsek; P Delmore; W H Edwards; J Hocker; A D Kantak; P Lewallen; W Lewis; E Lewit; C J McCarroll; D Mujsce; N R Payne; P Shiono; R F Soll; K Leahy; J H Carpenter
Journal:  Pediatrics       Date:  2001-01       Impact factor: 7.124

Review 3.  Primary care cardiology for patients with hypoplastic left heart syndrome.

Authors:  Jeffrey R Boris
Journal:  Cardiol Young       Date:  2011-12       Impact factor: 1.093

4.  Variation in preoperative and intraoperative care for first-stage palliation of single-ventricle heart disease: a report from the Joint Council on Congenital Heart Disease National Quality Improvement Collaborative.

Authors:  David W Brown; Jean A Connor; Frank A Pigula; Kudret Usmani; Thomas S Klitzner; Robert H Beekman; John D Kugler; Gerard R Martin; Steven R Neish; Geoffrey L Rosenthal; Carole Lannon; Kathy J Jenkins
Journal:  Congenit Heart Dis       Date:  2011 Mar-Apr       Impact factor: 2.007

5.  Normal interstage growth after the norwood operation associated with interstage home monitoring.

Authors:  David A Hehir; Nancy Rudd; Julie Slicker; Kathleen A Mussatto; Pippa Simpson; Shun-Hwa Li; Michele A Frommelt; James S Tweddell; Nancy S Ghanayem
Journal:  Pediatr Cardiol       Date:  2012-04-20       Impact factor: 1.655

6.  Home surveillance program prevents interstage mortality after the Norwood procedure.

Authors:  N S Ghanayem; G M Hoffman; K A Mussatto; J R Cava; P C Frommelt; N A Rudd; M M Steltzer; S M Bevandic; S S Frisbee; R D B Jaquiss; S B Litwin; J S Tweddell
Journal:  J Thorac Cardiovasc Surg       Date:  2003-11       Impact factor: 5.209

7.  Patient and practice factors affecting growth of infants with systemic-to-pulmonary shunt.

Authors:  Andrew W McCrary; Martha L Clabby; William T Mahle
Journal:  Cardiol Young       Date:  2012-10-08       Impact factor: 1.093

8.  Outcome of the Norwood operation in patients with hypoplastic left heart syndrome: a 12-year single-center survey.

Authors:  Anke Katharina Furck; Anselm Uebing; Jan Hinnerk Hansen; Jens Scheewe; Olaf Jung; Gunther Fischer; Carsten Rickers; Tim Holland-Letz; Hans-Heiner Kramer
Journal:  J Thorac Cardiovasc Surg       Date:  2009-10-30       Impact factor: 5.209

9.  Standardized management improves outcomes after the Norwood procedure.

Authors:  Chandra Srinivasan; Ritu Sachdeva; W Robert Morrow; Jeff Gossett; Carl W Chipman; Michiaki Imamura; Robert D B Jaquiss
Journal:  Congenit Heart Dis       Date:  2009 Sep-Oct       Impact factor: 2.007

10.  Interstage mortality after the Norwood procedure: Results of the multicenter Single Ventricle Reconstruction trial.

Authors:  Nancy S Ghanayem; Kerstin R Allen; Sarah Tabbutt; Andrew M Atz; Martha L Clabby; David S Cooper; Pirooz Eghtesady; Peter C Frommelt; Peter J Gruber; Kevin D Hill; Jonathan R Kaltman; Peter C Laussen; Alan B Lewis; Karen J Lurito; L LuAnn Minich; Richard G Ohye; Julie V Schonbeck; Steven M Schwartz; Rakesh K Singh; Caren S Goldberg
Journal:  J Thorac Cardiovasc Surg       Date:  2012-07-11       Impact factor: 5.209

View more
  1 in total

1.  Invasive Cardiac Procedures in Interstage Single Ventricle Patients in Emergent Hospitalizations.

Authors:  Brena S Haughey; Shelby C White; Garrett S Pacheco; Kenneth A Fox; Michael D Seckeler
Journal:  Pediatr Cardiol       Date:  2019-11-08       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.